Jason Coloma Sells 1,938 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 1,938 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $26.00, for a total value of $50,388.00. Following the completion of the sale, the chief executive officer owned 31,001 shares of the company’s stock, valued at approximately $806,026. The trade was a 5.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Down 0.2%

MAZE stock opened at $24.46 on Wednesday. The business’s 50-day moving average price is $32.59 and its 200-day moving average price is $37.87. The stock has a market cap of $1.35 billion, a P/E ratio of -9.67 and a beta of 2.50. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. Maze Therapeutics, Inc. has a twelve month low of $9.41 and a twelve month high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. On average, equities research analysts forecast that Maze Therapeutics, Inc. will post -2.65 EPS for the current year.

Institutional Trading of Maze Therapeutics

Hedge funds have recently modified their holdings of the company. Royal Bank of Canada grew its holdings in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Maze Therapeutics during the fourth quarter valued at $39,000. Ameritas Investment Partners Inc. lifted its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Maze Therapeutics during the fourth quarter valued at $43,000. Finally, Russell Investments Group Ltd. grew its stake in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after buying an additional 1,725 shares in the last quarter.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Neutral Sentiment: HC Wainwright still rates Maze Therapeutics as a Buy and maintains a $110 target, suggesting the firm remains constructive on the long-term story despite trimming near- and medium-term earnings estimates.
• Negative Sentiment: HC Wainwright cut Q2 2026 EPS estimates to a larger loss, reinforcing concerns that Maze may take longer to improve profitability than previously expected.
• Negative Sentiment: HC Wainwright also lowered Q3, Q4, FY2026, FY2027, FY2028, FY2029 and FY2030 EPS forecasts, signaling a broader reduction in earnings expectations across the company’s growth horizon.
• Negative Sentiment: Recent insider selling by the CEO and CMO may be adding pressure on MAZE shares, as investors often view executive stock sales cautiously even when they occur under trading plans.

Wall Street Analyst Weigh In

MAZE has been the topic of a number of analyst reports. Wedbush lifted their target price on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright boosted their price objective on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. JPMorgan Chase & Co. upped their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. Finally, Truist Financial cut their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, April 14th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.